MARKET

AFMD

AFMD

Affimed
NASDAQ

Real-time Quotes | Nasdaq Last Sale

9.62
+0.11
+1.16%
After Hours: 9.28 -0.34 -3.53% 19:54 04/19 EDT
OPEN
9.28
PREV CLOSE
9.51
HIGH
9.84
LOW
9.22
VOLUME
2.05M
TURNOVER
--
52 WEEK HIGH
10.79
52 WEEK LOW
1.880
MARKET CAP
1.01B
P/E (TTM)
-15.7757
1D
5D
1M
3M
1Y
5Y
AACR 2021 highlights Eli Lilly’s new KRAS battle; Affimed’s Natural Killer cell therapy
The first week of AACR 2021 (American Association of Cancer Research Annual Meeting) has concluded with Affimed (AFMD) emerging as a clear winner while iTeos Therapeutics (ITOS) disappointed with an
Seekingalpha · 2d ago
Natural Killer Cells and Other Promising Cancer Treatments
Barrons.com · 4d ago
DJ 'Natural Killer Cells' and Other Promising Cancer Treatments -- Barrons.com
Dow Jones · 4d ago
Affimed trades lower following FY bottom-line miss
Affimed ([[AFMD]] -7.8%) FY results:Revenue of €28.4M (+32.7% Y/Y).Operating Loss: (€34.72M) (-7.23%); Net Loss: (€41.37M) (-27.80%); Loss Per Share: (€0.50) (flat Y/Y).Quick Assets: €146.9M, with anticipated cash runway into 2H of 2023.KEY milestones: AFM...
Seekingalpha · 4d ago
Ardelyx, Liquidia leads healthcare gainers; Zomedica, Affimed among major losers
Gainers: Ardelyx (ARDX) +13%, Liquidia (LQDA) +9%, PPD (PPD) +7%, Inovio Pharmaceuticals (INO) +6%, BiomX (PHGE) +6%.Losers: Zomedica (ZOM) -12%, Affimed (AFMD) -10%, Aesthetic Medical International (AIH) -7%, Galectin Therapeutics (GALT) -8%, Ekso Bionics...
Seekingalpha · 4d ago
XOMA's Royalty Portfolio Grows with Addition of Three Royalty Assets
XOMA Corporation (Nasdaq: XOMA) today announced its portfolio of potential future milestone and royalty assets has increased with the addition of three Affimed N.V. (Nasdaq: AFMD) innate cell engager (ICE) programs for which XOMA could receive future econo...
GlobeNewswire · 4d ago
The Daily Biotech Pulse: Merck Shelves 2 COVID-19 Studies, Bristol-Myers Squibb Gets European Regulatory Nod, InspireMD's Reverse Split
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 14)
Benzinga · 4d ago
XOMA Adds Three Royalty Assets From Affimed
MT Newswires · 4d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of AFMD. Analyze the recent business situations of Affimed through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average AFMD stock price target is 15.43 with a high estimate of 18.11 and a low estimate of 14.08.
EPS
Institutional Holdings
Institutions: 151
Institutional Holdings: 64.23M
% Owned: 61.18%
Shares Outstanding: 104.99M
TypeInstitutionsShares
Increased
50
12.18M
New
31
5.25M
Decreased
34
5.57M
Sold Out
6
1.17M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-1.60%
Pharmaceuticals & Medical Research
-0.26%
Key Executives
Chairman - Supervisory/Independent Director
Thomas Hecht
President/Management Board
Denise Mueller
Chief Executive Officer/Management Board
Adi Hoess
Chief Financial Officer
Angus Smith
Chief Operating Officer/Management Board
Wolfgang Fischer
Chief Scientific Officer/Management Board
Arndt Schottelius
Management Board
Andreas Harstrick
Independent Director/Supervisory Board
Bernhard Ehmer
Independent Director/Supervisory Board
Ulrich Grau
Independent Director/Supervisory Board
Berndt Modig
Independent Director/Supervisory Board
Mathieu Simon
Independent Director/Supervisory Board
Ferdinand Verdonck
Supervisory Board
Annalisa Jenkins
Supervisory Board
Harry Welten
No Data
  • All
  • Financials
  • Insiders
More
About AFMD
Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Company's product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body's own immune system to fight tumor cells. Its pipeline includes AFM13, AFM13 + adoptive NK cells, AFM13 + anti-PD-1, AMF24, AMF26, AMF28 and AMF32. The Company is enrolling patients into a registration-directed study of AFM13 for CD30-positive relapsed/refractory peripheral T-cell Lymphoma and into a Phase 1/2a dose escalation/expansion study of AFM24 for the treatment of advanced EGFR-expressing solid tumors. Its preclinical product candidates include AMF26 for treating multiple myeloma, as well as AMF28 and AMF32, for treating of multiple tumor targets. In addition, the Company collaborates with Genentech to develop and commercialize certain product candidates for treating multiple cancers.

Webull offers kinds of Affimed NV stock information, including NASDAQ:AFMD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AFMD stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AFMD stock methods without spending real money on the virtual paper trading platform.